^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Ovarian Cancer
    Drug:adavosertib (AZD1775) (WEE1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

    Excerpt:
    ...Confirmed BRCA1 or BRCA2 mutation from a prior test....
    Trial ID:
    NCT02482311
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Target Oncol
    Title:

    A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors

    Published date:
    06/06/2023
    Excerpt:
    Objective response rate, disease control rate, and progression-free survival were as follows: 6.3%, 68.8%, 4.5 months (OC BRCA wild type); 3.3%, 76.7%, 3.9 months (OC BRCA mutation)....Median PFS was...3.9 months in the ovarian cancer, BRCAm....Adavosertib monotherapy was tolerated and demonstrated some antitumor activity in patients with advanced solid tumors.
    DOI:
    10.1007/s11523-023-00965-7